Eli Lilly and (NYSE: LLY) and Innocoll Holdings PLC (NASDAQ:INNL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitabiliy.

Dividends

Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Innocoll Holdings PLC does not pay a dividend. Eli Lilly and pays out 90.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Innocoll Holdings PLC has raised its dividend for 2 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Eli Lilly and and Innocoll Holdings PLC, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and 1 6 11 0 2.56
Innocoll Holdings PLC 0 3 1 0 2.25

Eli Lilly and currently has a consensus price target of $89.18, suggesting a potential upside of 8.34%. Innocoll Holdings PLC has a consensus price target of $4.50, suggesting a potential upside of 91.49%. Given Innocoll Holdings PLC’s higher possible upside, analysts plainly believe Innocoll Holdings PLC is more favorable than Eli Lilly and.

Institutional & Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 34.2% of Innocoll Holdings PLC shares are owned by institutional investors. 0.2% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Eli Lilly and and Innocoll Holdings PLC’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eli Lilly and $22.00 billion 3.95 $5.99 billion $2.31 35.63
Innocoll Holdings PLC N/A N/A N/A ($1.67) -1.41

Eli Lilly and has higher revenue and earnings than Innocoll Holdings PLC. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eli Lilly and has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Innocoll Holdings PLC has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Profitability

This table compares Eli Lilly and and Innocoll Holdings PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eli Lilly and 11.12% 28.71% 10.74%
Innocoll Holdings PLC -1,051.20% N/A -138.53%

Summary

Eli Lilly and beats Innocoll Holdings PLC on 11 of the 14 factors compared between the two stocks.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Innocoll Holdings PLC Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.